All News
Will AI put me out of a job?
The development of AI and other technologies brings new possibilities for optimizing diagnosis, management and has potential for improving outcomes in RA. At RheumNow Live 2025, Dr. Jeff Curtis, University of Alabama at Birmingham, presented a talk on, "AI applied to Rheumatoid Arthritis Care: Practically (Not) Perfect".
Read Article
Obinutuzumab Efficacy in Active Lupus Nephritis
A phase 3, randomized controlled trial of an anti-CD20 monoclonal antibody, obinutuzumab, was shown to be effective and safe in patients with active lupus nephritis.
Read Article
“Preventing” Arthritis in Psoriasis
The always compelling Dr. Alexis Ogdie explored whether aggressive treatment of psoriasis can prevent psoriatic arthritis in an excellent Saturday morning session at RheumNow Live 2025.
Read Article
Drug Naming Games (2.7.2025)
Dr. Jack Cush reviews the news, regulatory and journal reports from the past week on RheumNow.com.
Read Article
Eric Dein @ericdeinmd
AI models require good Positive Predictive Value (PPV) But: PPV decreases as prevalence decreases - In choosing a successful biologic: Harder to predict more challenging patients (multiple failures, co-morbidities, etc) - ACR50 non-response is higher J… https://t.co/eAOR0jFmO3 https://t.co/TB6Ecd8nZh
Dr. John Cush RheumNow ( View Tweet)
Adela Castro @AdelaCastro222
How can AI be useful for RA pts and rheumatologists? -AI models have the potential for improving diagnosis, management and outcomes in RA pts. -Can also improve efficiency and clinic workflow. -Not so perfect as it sounds (hallucinations, limited… https://t.co/YA4A990p2v https://t.co/YnHtbP83Nm
Dr. John Cush RheumNow ( View Tweet)
Study of 702 pts who transitioned from PsO to PsA (median 9yrs) - no baseline differences in PsA pts who transitioned late (>9yrs); but on follow-up, the late group had lower Dz activity, less csDMARD use, but no difference in radiographic progression https://t.co/vwgfa5z6BE https://t.co/N1yUcrcR2o
Links:
Dr. John Cush RheumNow ( View Tweet)
P2 Trial: DEU in PsA
Encouraging results for DCV 6 and 12 mg qd.
ACR20 63% for DCV 12 mg (p=0.0004)
Not yet FDA approved for PsA, only PsO
Pending P3
P2: DEU in SLE - PAISLEY
Improved SRI(4), CLASI-50 at w32
Merola
#RNL2025 @RheumNow https://t.co/RV7OPaZWjx
Links:
Eric Dein ericdeinmd ( View Tweet)
Pearls on Dermatomyositis:
-Negative myomarker does not r/o DM
-Pruritus can be a skin manifestation in DM🚨
-Combination therapy upfront =achieve faster remission
-Evidence for JAK inhibitors in management
-JAKis seem to have good effect in DM-calcinosis
-In DM with rapidly… https://t.co/J3iiDa6ph7 https://t.co/0WTHKa97bt
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Can treatment of PsO prevent PsA?
-Severity of PsO and obesity->Risk fx for PsA
-PRESTO scores: Predicts whether you will develop PsA in the next year vs next 5 years
-Does ttx of PsO impact development of PsA?
Trials are mostly observational (several confounders)
TriNetX data:… https://t.co/TBv3Y2TLZv https://t.co/1K0MtMQ5gn
Links:
Adela Castro AdelaCastro222 ( View Tweet)
M. Petri on Steroids in SLE👇
-Organ damage is higher in AA vs Caucasians-driven by CS
-CV risk increase is dose dependent:
>10 mg =2x risk
>20mg =5x risk
-Increase prednisone by 10mg =30% increased risk for organ damage! 🤯
-20mg/day >1m increases risk for… https://t.co/fZVjS7JQBL
Adela Castro AdelaCastro222 ( View Tweet)
Wise person once said
If you don’t take your medications,
THEY DON’T WORK!
Shocking 1 in 3 nonadherence with
#hydroxychloroquine
By drug levels
In young Pts with
#SLE #lupus
Michelle Petri @RheumNow #RNL2025 https://t.co/H5izbnW0qU
Janet Pope Janetbirdope ( View Tweet)
How can AI be useful for RA pts and rheumatologists?
-AI models have the potential for improving diagnosis, management and outcomes in RA pts.
-Can also improve efficiency and clinic workflow.
-Not so perfect as it sounds (hallucinations, limited accuracy)
#RNL2025 @RheumNow https://t.co/44LUHQ1KPf
Adela Castro AdelaCastro222 ( View Tweet)
AI models require good Positive Predictive Value (PPV)
But: PPV decreases as prevalence decreases
- In choosing a successful biologic:
Harder to predict more challenging patients (multiple failures, co-morbidities, etc) - ACR50 non-response is higher
J Curtis
@RheumNow #RNL2025 https://t.co/SdJ0FHVuSC
Eric Dein ericdeinmd ( View Tweet)
#AI can help with Value Based Care…a year in remission for RA will save a lot of money. @RADoctor @rheumnow #RNL2025 https://t.co/rUpeMrDHZf
TheDaoIndex KDAO2011 ( View Tweet)
Such an important topic from @UnaMakris . The intersection of aging with our rheumatic disease processes is a crucial area. @RheumNow @RNL2025 https://t.co/n0Kx559g9e
Richard Conway RichardPAConway ( View Tweet)
Is Rheumatoid Arthritis Becoming Milder?
A 24 year, prospective study analyzing very early rheumatoid arthritis (RA) in three consecutive eras suggests that RA has evolved since 2005, demonstrating less seropositivity, inflammation, and erosions but is characterized by more… https://t.co/y50uCU79i9 https://t.co/crKytLY4WN
Dr. John Cush RheumNow ( View Tweet)
Pain Management in Rheumatoid Arthritis
BMC has published a full read literture review of pharmacological pain management in rheumatoid arthritis, pointing out that the best evidence for pain control comes from the use of DMARDs and treat-to-target strategies.… https://t.co/1rcTxpQxxT https://t.co/s20bg5FJqQ
Dr. John Cush RheumNow ( View Tweet)
TNF inhibitor use did not affect mortality outcomes in 3 cohorts w/ early Cancer (colorectal [514], lung [864], & prostate [603]). 12-20% of CA pts recv TNFi. Overall survival at Yr 1 unaffected in colorectal (HR 0·72; 0·43–1·21), Lung (0·70; 0·49–1·00), Prostate (0·80;… https://t.co/Pi8rNuvioO
Dr. John Cush RheumNow ( View Tweet)
Overweight & obesity increase risk of Chr. Inflammatory Dz (CIDs). TriNetX EHR study of >3.1 million persons shows risk of any CID=28.5% in overweight/obese vs. 17.6% in controls (HR 1.52). Overweight/obesity posed a > risk of 4 CIDs in females & also >risk for 7 CIDs in Whites… https://t.co/U5ydFGolIY https://t.co/b3Jpl27wLf
Dr. John Cush RheumNow ( View Tweet)
